Biologics Spine BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data byTim AllenNovember 13, 2024
Biologics Regulatory BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health byTim AllenNovember 5, 2024
Financial BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update byJosh SandbergAugust 13, 2024
Financial BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results byTim AllenJune 17, 2024
Regulatory Spine BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment byTim AllenApril 16, 2024
Spine BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease byTim AllenApril 8, 2024
Financial BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K byTim AllenApril 1, 2024
Financial BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market byJosh SandbergFebruary 6, 2024
Spine BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease byJosh SandbergFebruary 5, 2024
Biologics Spine BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting byJosh SandbergFebruary 1, 2024
